83 related articles for article (PubMed ID: 980285)
1. Cell-mediated immunity and blocking factor in ovarian carcinoma.
Mitchell MS; Kohorn EI
Obstet Gynecol; 1976 Nov; 48(5):590-7. PubMed ID: 980285
[TBL] [Abstract][Full Text] [Related]
2. Expression of cell-mediated immunity and blocking factor using a new line of ovarian cancer cells in vitro.
Pattillo RA; Story MT; Ruckert AC
Cancer Res; 1979 Apr; 39(4):1185-92. PubMed ID: 421202
[TBL] [Abstract][Full Text] [Related]
3. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
4. Nutrition and tumor immunity: divergent effects of antitumor antibody.
Bull DM
Cancer Res; 1975 Nov; 35(11 Pt. 2):3317-9. PubMed ID: 1104143
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.
Allavena P; Peccatori F; Maggioni D; Erroi A; Sironi M; Colombo N; Lissoni A; Galazka A; Meiers W; Mangioni C
Cancer Res; 1990 Nov; 50(22):7318-23. PubMed ID: 2121337
[TBL] [Abstract][Full Text] [Related]
6. Serotherapy of ovarian cancer.
Lidor Y; Bast RC
Nat Immun Cell Growth Regul; 1988; 7(4):193-215. PubMed ID: 3070370
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy.
Bjørge L; Stoiber H; Dierich MP; Meri S
Scand J Immunol; 2006 May; 63(5):355-64. PubMed ID: 16640659
[TBL] [Abstract][Full Text] [Related]
8. Investigations on cell-mediated immunity in patients with breast and ovarian carcinomas receiving a combination of chemotherapy and immunotherapy with thymopentin.
Mallmann P; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Jun; 12(5):333-40. PubMed ID: 2232966
[TBL] [Abstract][Full Text] [Related]
9. Detection of malignant ovarian neoplasms: a review of the literature. III. Immunological detection and ovarian cancer-associated antigens.
Smith LH; Oi RH
Obstet Gynecol Surv; 1984 Jun; 39(6):346-60. PubMed ID: 6203071
[TBL] [Abstract][Full Text] [Related]
10. Problems in the clinical use of the microcytotoxicity assay for measuring cell-mediated immunity to tumor cells.
Heppner G; Henry E; Stolbach L; Cummings F; McDonough E; Calabresi P
Cancer Res; 1975 Aug; 35(8):1931-7. PubMed ID: 1149017
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
12. [Studies on host immunity in cervical cancer--alterations in nonspecific and specific immunity of tumor growth (author's transl)].
Yamada Y
Nihon Sanka Fujinka Gakkai Zasshi; 1980 Nov; 32(11):1820-8. PubMed ID: 7240835
[TBL] [Abstract][Full Text] [Related]
13. [Nonspecific cell-mediated immunity of gynecologic cancer patients and related effects of chemotherapy and immunotherapy].
Takada M
Gan To Kagaku Ryoho; 1983 Jun; 10(6):1480-5. PubMed ID: 6409005
[TBL] [Abstract][Full Text] [Related]
14. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
15. Studies on the induction and expression of T cell-mediated immunity. XIV. Antigen-nonspecific oxidation-dependent cellular cytotoxicity (ODCC) mediated by sodium periodate oxidation of cytotoxic T lymphocytes.
Fan J; Bonavida B
J Immunol; 1983 Sep; 131(3):1426-32. PubMed ID: 6193189
[TBL] [Abstract][Full Text] [Related]
16. Cell-mediated immune mechanisms of tumor cell destruction.
Perlmann P; O'Toole C; Unsgaard B
Fed Proc; 1973 Feb; 32(2):153-5. PubMed ID: 4540104
[No Abstract] [Full Text] [Related]
17. Demonstration of cell-mediated and humoral antibodies in patients with malignant breast and ovary-tumours.
Kitschke HJ; Krebs D
Acta Eur Fertil; 1973 Jun; 4(2):75-7. PubMed ID: 4784141
[No Abstract] [Full Text] [Related]
18. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
[TBL] [Abstract][Full Text] [Related]
19. Ovarian tumor antigens: a new potential for therapy.
Order SE; Thurnston J; Knapp R
Natl Cancer Inst Monogr; 1975 Oct; 42():33-43. PubMed ID: 1234634
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
